Anthrax
HHS, Emergent BioSolutions enter into contract for anthrax vaccine development
The U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) recently moved forward with the development of the anthrax vaccine NuThrax. ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and Emergent... Read More »
Emergent BioSolutions, Inc., signs multi-year contract for next-gen anthrax vaccine candidate
Emergent BioSolutions, Inc., announced on Friday that it has signed a multi-year contract for the advanced development and delivery of NuThrax (vaccine adsorbed with CPG 7909 adjuvant), the company’s next-generation anthrax vaccine candidate. The contract, signed with the Biomedical Advanced... Read More »
Elusys Therapeutics publishes clinical trial data supporting approval for anthrax treatment
Elusys Therapeutics, Inc., published data on Thursday on more than 450 healthy adult subjects from five clinical trials used to support recent U.S. Food and Drug Administration (FDA) marketing approval of ANTHIM injection. ANTHIM is used in adult and pediatric patients for the treatment of... Read More »
FDA approves sBLA for Biothrax manufacture at Emergent BioSolutions’ Building 55
The U.S. Food and Drug Administration (FDA) recently approved Emergent BioSolutions, Inc.’s supplemental Biologics License Application (sBLA) for the manufacture of BioThrax (Anthrax Vaccine Adsorbed) at the company’s large-scale Building 55 manufacturing facility in Lansing,... Read More »
Altimmune, BARDA set for clinical trial of single-dose anthrax vaccine
Altimmune, Inc., and the Biomedical Advanced Research and Development Authority (BARDA) are set to advance the first clinical trial later this month of an anthrax vaccine that could be administered in a single dose. The trial was initiated from a two-year, $14 million contract between BARDA and... Read More »